BGM0504 is named as an intervention in 5 current clinical trials in our China and USA registers. 5 are recruiting patients now. The most common phase is Phase 1. The sponsor with the most trials is BrightGene Bio-Medical Technology Co., Ltd (4). The most-studied condition is Non-diabetic Overweight or Obese.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study of BGM0504 Injection in Participants with Obesity or Overweight
NCT06704581 · ClinicalTrials.gov ↗ · Overweight or Obesity
|
Phase 3 | Recruiting | BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd. | China |
|
A Study of BGM0504 in Early T2DM With Obesity
NCT07743983 · ClinicalTrials.gov ↗ · Type 2 Diabetes (T2DM)
|
Phase 3 | Recruiting | BrightGene Bio-Medical Technology Co., Ltd. | China |
|
A Study of BGM0504 in Participants With Obesity
NCT06911203 · ClinicalTrials.gov ↗ · Obesity
|
Phase 2 | Recruiting | BrightGene Bio-Medical Technology Co., Ltd. | China |
|
Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult Subjects
NCT07166081 · ClinicalTrials.gov ↗ · Non-diabetic Overweight or Obese
|
Phase 1 | Recruiting | BrightGene Bio-Medical Technology Co., Ltd. | USA |
|
A Study of BGM0504 Tablets in Healthy Chinese Subjects
NCT07566572 · ClinicalTrials.gov ↗ · Chinese Healthy Volunteers
|
Phase 1 | Recruiting | BrightGene Bio-Medical Technology Co., Ltd. | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| BrightGene Bio-Medical Technology Co., Ltd. | 4 |
| BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd. | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 4 | 4 |
| Clinical trials in USA | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
5 current trials in our China and USA registers name BGM0504 as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 5 of the 5 trials are recruiting: 4 with sites in China and 1 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
BrightGene Bio-Medical Technology Co., Ltd (4) and BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how BGM0504 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how BGM0504 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists BGM0504 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.